Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia

Supplemental Digital Content is available in the text. Our previous research has shown that monocytic leukemia–associated antigen-34 (MLAA-34) was a novel antiapoptotic molecule with unique expression in acute monocytic leukemia (M5), making it an ideal target for T-cell–based immunotherapy. Here, we sought to identify HLA-A*0201-restricted cytotoxic T-lymphocyte (CTL) epitope of MLAA-34 by reverse immunology. In all, 10 HLA-A*0201 restricted epitopes of MLAA-34 were predicted by bioinformatics. MLAA-34324–332, MLAA-34293–301, and MLAA-34236–244 showed the strongest HLA-A*0201-binding affinity. The percentages of HLA-A*0201-MLAA-34236–244 tetramer+ CD8+ T cells in MLAA-34236–244-induced CTLs were raised apparently. Enzyme-linked immunospot showed that MLAA-34236–244 and MLAA-34324–332-specific CTLs produced a higher amount of interferon-γ. MLAA-34236–244-induced CTLs presented a stronger cytotoxic effect on THP-1 cells (HLA-A*0201+MLAA-34+) at various effector to target ratios. MLAA-34236–244 peptide vaccine could inhibit the tumor growth and improve mean survival time of leukemia-bearing human peripheral blood lymphocyte reconstituting severe combined immunodeficient mice. Mice immunized with MLAA-34236–244 vaccine had increased percentages of MLAA-34236–244 tetramer+ CD8+ T cells in the spleen after each round of immunization. High-purity CD8+ and CD4+ T cells were sorted by Dynabeads as effector cells. The killing activity of CD8+ T cells was higher than that of CD4+ T cells. CTLs derived from the MLAA-34 peptide vaccine group were significantly higher than other therapeutic groups and showed specific cytotoxicity to THP-1 cells. Increased interferon-γ and interleukin (IL)-2 and decreased IL-10 and IL-4 were seen in the MLAA-34236–244 peptide vaccine group. MLAA-34236–244 peptide (ILDRHNFAI) is an effective HLA-A*0201-restricted CTL epitope and that it may serve as a promising strategy in designing antigen-specific immunotherapy against MLAA-34-positive acute monocytic leukemia.

[1]  K. Ishiyama,et al.  Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia , 2020, Leukemia.

[2]  N. Munshi,et al.  Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy , 2019, Leukemia.

[3]  S. Gill,et al.  Novel Approaches to Acute Myeloid Leukemia Immunotherapy , 2018, Clinical Cancer Research.

[4]  N. Hosen,et al.  Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy , 2017, Oncology Research and Treatment.

[5]  Yanfeng Gao,et al.  A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo. , 2017, Protein and peptide letters.

[6]  Zong-fang Li,et al.  A novel multi‐epitope vaccine from MMSA‐1 and DKK1 for multiple myeloma immunotherapy , 2017, British journal of haematology.

[7]  Hyunjoo Lee,et al.  Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia , 2017, Oncotarget.

[8]  P. Thall,et al.  PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies , 2016, Leukemia.

[9]  N. Coltella,et al.  Hypoxia inducible factor-1α regulates a pro-invasive phenotype in acute monocytic leukemia , 2016, Oncotarget.

[10]  B. Lei,et al.  The anti-apoptosis effect of MLAA-34 in leukemia and the β-catenin/T cell factor 4 protein pathway. , 2015, American journal of translational research.

[11]  Wanggang Zhang,et al.  Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes , 2014, Medical Oncology.

[12]  W. Hiddemann,et al.  Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Wen-juan Zhang,et al.  The expression and functional characterization associated with cell apoptosis and proteomic analysis of the novel gene MLAA-34 in U937 cells. , 2013, Oncology reports.

[14]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[15]  T. Kyo,et al.  Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease , 2012, Leukemia.

[16]  B. Delahunt,et al.  Allergen-Specific CTL Require Perforin Expression To Suppress Allergic Airway Inflammation , 2012, The Journal of Immunology.

[17]  Lin Zhao,et al.  Identification of novel HLA-A(*)0201-restricted CTL epitopes from Pokemon. , 2012, Cellular immunology.

[18]  N. Kadowaki,et al.  Recent Advance in Antigen-Specific Immunotherapy for Acute Myeloid Leukemia , 2011, Clinical & developmental immunology.

[19]  Xin Meng,et al.  Quantitative assessment of MLAA-34 expression in diagnosis and prognosis of acute monocytic leukemia , 2011, Cancer Immunology, Immunotherapy.

[20]  H. Döhner,et al.  High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma , 2010, Haematologica.

[21]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[22]  Wen-Bin Li,et al.  Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34 , 2009, Cancer Immunology, Immunotherapy.

[23]  P. Romero,et al.  Reverse immunology approach for the identification of CD8 T‐cell‐defined antigens: Advantages and hurdles , 2006, Immunology and cell biology.

[24]  Mads Hald Andersen,et al.  Cytotoxic T cells. , 2006, The Journal of investigative dermatology.

[25]  H. Döhner,et al.  Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. , 2005, Blood.

[26]  M. Nishimura,et al.  A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity. , 2005, Cancer letters.

[27]  L. Yao,et al.  Serological identification of immunogenic antigens in acute monocytic leukemia. , 2005, Leukemia research.

[28]  H. Sugiyama,et al.  Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product , 2000, Immunogenetics.

[29]  S. Fujita,et al.  HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. , 2000, Blood.

[30]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.